The CHMP has recommended approval of Jorveza oral suspension 0.2 mg/mL, the first licensed pediatric formulation of ...

The investigational monoclonal antibody cendakimab significantly improved symptoms and reduced esophageal eosinophils in patients with eosinophilic esophagitis at 24 weeks, a randomized phase III ...

For initial treatment of eosinophilic esophagitis (EoE), an elimination diet is the most cost-effective option from a payer perspective and proton pump inhibitor (PPI) therapy is more cost-effective ...

Please provide your email address to receive an email when new articles are posted on . The impact of food elimination diets on medication previously was unknown. Absolute mean changes in Dysphagia ...

Navigating everyday life with eosinophilic esophagitis (EoE) can come with challenges, and those can be magnified when you’re traveling. Figuring out which foods are safe to eat, being far from your ...

Benralizumab is an eosinophil-depleting anti–interleukin-5 receptor α monoclonal antibody. The efficacy and safety of benralizumab in patients with eosinophilic esophagitis are unclear. In a phase 3, ...

New research shows PPIs can limit fibrosis in eosinophilic oesophagitis, offering potential disease-modifying effects. Learn more about PPI therapy.

For people with eosinophilic esophagitis (EoE), a chronic immunologic disease, eating and diet arent always a piece of cake. In response to an allergen usually one or more food groups the lining of ...